| Date | Title | Description | Source |
| 03.01.2024 | Global Mofy Metaverse Limited Announces the Closing of $10 M... | - | globenewsw... |
| 29.12.2023 | Global Mofy Metaverse Limited Announces $10 Million Follow-o... | - | globenewsw... |
| 20.10.2023 | Webuy Global Limited Announces Closing of $15.2 Million Init... | - | globenewsw... |
| 18.10.2023 | Webuy Global Limited Announces Pricing of $15.2 Million Init... | - | globenewsw... |
| 12.10.2023 | Global Mofy Metaverse Limited Announces Closing of $6,000,00... | - | globenewsw... |
| 05.07.2023 | SRC Signs a 3-year Sponsorship Deal With Saudi Football Club... | SRC signs with Al Ittihad FC RIYADH, DUBAI, SAUDI ARABIA, July 5, 2023/EINPresswire.com/ -- The Saud... | einpresswi... |
| 13.06.2023 | Autifony Therapeutics announces commencement of a US Phase I... | Stevenage, UK - 13 June 2023 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the d... | svhealthin... |
| 10.06.2023 | HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Li... | /EIN News/ -- NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (N... | einpresswi... |
| 17.04.2023 | VCI Global Limited Announces Closing of $5.12 Million Initia... | - | globenewsw... |
| 17.04.2023 | VCI Global Limited Announces Closing of $5.12 Million Initia... | /EIN News/ -- KUALA LUMPUR, Malaysia, April 17, 2023 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ:... | einpresswi... |
| 14.04.2023 | HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Li... | /EIN News/ -- NEW YORK and VIENNA, Austria, April 14, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (... | einpresswi... |
| 29.11.2022 | Poolbeg Pharma PLC Announces Influenza AI model build comple... | Influenza Artificial Intelligence model build completed
CytoReason analysis of human challenge trial... | accesswire... |
| 17.11.2022 | Poolbeg Pharma PLC Announces Capital Markets Day | LONDON, UK / ACCESSWIRE / November 17, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or t... | accesswire... |
| 17.11.2022 | Poolbeg Pharma PLC Announces Capital Markets Day | LONDON, UK / ACCESSWIRE / November 17, 2022 / Poolbeg Pharma POLBPOLBF, 'Poolbeg' or the 'Company', ... | einpresswi... |
| 08.11.2022 | Poolbeg Pharma PLC Announces AI Programme Yields Novel RSV D... | First time AI has been used to identify disease targets in RSV
LONDON, UK / ACCESSWIRE / November 8... | einpresswi... |
| 20.10.2022 | HOOKIPA announces strategic collaboration and license agreem... | Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed nov... | globenewsw... |
| 04.10.2022 | Poolbeg Pharma PLC Announces POLB 001 US Patent update | Continued expansion of IP portfolio enhancing protection of Poolbeg's growing pipeline
LONDON, UK /... | accesswire... |
| 29.07.2022 | Poolbeg Pharma PLC Announces Appointment of Joint Broker | LONDON, UK / ACCESSWIRE / July 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the '... | accesswire... |
| 20.07.2022 | Poolbeg Pharma PLC Announces POLB001 Human Challenge Clinica... | Major milestone reached as POLB 001 human challenge clinical trial ready to commence
Regulatory app... | accesswire... |
| 08.07.2022 | Global SPAC Partners Announces Confirmation of $41.9 million... | New York NY, July 08, 2022 (GLOBE NEWSWIRE) -- Global SPAC Partners Co. (“Global”) (Nasdaq: “GLSPU” ... | globenewsw... |
| 16.05.2022 | HOOKIPA Pharma Reports First Quarter 2022 Financial Results ... | HB-200 program on track to report Phase 1 data mid-year, Phase 2 data in combination with pembrolizu... | globenewsw... |
| 09.05.2022 | HOOKIPA Pharma to Report First Quarter 2022 Financial Result... | NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘H... | globenewsw... |
| 03.05.2022 | HOOKIPA Pharma to Participate in Upcoming Investor Conferenc... | NEW YORK and VIENNA, Austria, May 03, 2022 (GLOBE NEWSWIRE) -- New York, US and Vienna, Austria, May... | globenewsw... |
| 13.04.2022 | HOOKIPA to Participate in the Kempen Life Sciences Conferenc... | NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ... | globenewsw... |
| 04.04.2022 | Poolbeg Pharma PLC Announces Result of AGM | LONDON, UK / ACCESSWIRE / April 4, 2022 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the 'C... | accesswire... |
| 31.03.2022 | Poolbeg Pharma PLC Announces POLB001 Update - Clinical Trial... | On track to commence LPS human challenge clinical trial in June 2022
LONDON, UK / ACCESSWIRE / Marc... | accesswire... |
| 30.03.2022 | Poolbeg Pharma PLC Announces Commencement of Trading on US O... | Poolbeg Pharma commences trading on OTCQB Market in the United States
LONDON, UK / ACCESSWIRE / Mar... | accesswire... |
| 24.03.2022 | HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial ... | Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging a... | globenewsw... |
| 02.03.2022 | HOOKIPA Pharma Announces Pricing of $75.0 Million Public Off... | NEW YORK and VIENNA, Austria, March 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK),... | globenewsw... |
| 15.02.2022 | HOOKIPA and Gilead Amend Collaboration and License Agreement... | HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; ... | globenewsw... |
| 09.02.2022 | HOOKIPA to Present at the SVB Leerink Global Healthcare Conf... | NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘... | globenewsw... |
| 04.02.2022 | Altus Announces Leadership Transition Plan, Preliminary Fina... | Conference Call Scheduled for 5:30 pm ET Today
TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Altus Gro... | marketscre... |
| 03.02.2022 | Altus Announces Leadership Transition Plan, Preliminary Fina... | TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Altus Group Limited (TSX: AIF) (the “Company” or “Altus”)... | globenewsw... |
| 18.01.2022 | HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Ev... | First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/met... | globenewsw... |
| 04.01.2022 | HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect ... | NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘... | globenewsw... |
| 12.11.2021 | HOOKIPA Pharma to Participate in Upcoming Stifel 2021 Virtua... | NEW YORK and VIENNA, Austria, Nov. 12, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘... | globenewsw... |
| 10.11.2021 | HOOKIPA Pharma Reports Third Quarter 2021 Financial Results ... | Clinical collaboration with Merck & Co., Inc., Kenilworth, NJ, USA, set to evaluate HB-201 in co... | globenewsw... |
| 09.11.2021 | HOOKIPA advances HB-200 program to Phase 2 and prioritizes o... | Based on positive interim Phase 1 data, HOOKIPA initiates Phase 2 study to assess HB-201 in combinat... | globenewsw... |
| 14.10.2021 | HOOKIPA announces publication on the benefits of its novel a... | Comprehensive review highlights potential of HOOKIPA’s versatile arenavirus platform as a new immuno... | globenewsw... |
| 15.04.2021 | Alchemab raises £60M ($82M) in Series A financing to advance... | April 15, 2021 04:00 AM Eastern Daylight Time
CAMBRIDGE, England--(BUSINESS WIRE)--Alchemab Therape... | svhealthin... |
| 13.04.2021 | GLOBAL SPAC PARTNERS CO.
Global SPAC Partners Co. Announces... | New York, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Global SPAC Partners Co. (“Global” or the “Co... | marketscre... |
| 10.04.2021 | HOOKIPA PHARMA INC.
HOOKIPA announces positive preliminary ... | Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of cir... | marketscre... |
| 09.04.2021 | GLOBAL SPAC PARTNERS CO.
Global SPAC Partners Co. Announces... | New York, New York, April 08, 2021 (GLOBE NEWSWIRE) -- Global SPAC Partners Co. (“Global” or the “Co... | marketscre... |
| 26.03.2021 | LEKOIL LIMITED
Lekoil : Trading and operational update | RNS Number : 5635T Lekoil Limited
26 March 2021
26 March 2021
Lekoil Limited
("LEKOIL"... | marketscre... |
| 23.03.2021 | Oxford BioDynamics announces US launch of its EpiSwitch® COV... | OXFORD, England--(BUSINESS WIRE)--Mar 23, 2021--
Oxford BioDynamics Plc (AIM: OBD, the Company), a ... | oaoa.com/n... |
| 18.03.2021 | HOOKIPA Reports Fourth Quarter and Full Year 2020 Financial ... | Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with int... | globenewsw... |
| 16.03.2021 | Alchemab and Medicines Discovery Catapult to develop landmar... | March 16, 2021 05:00 AM Eastern Daylight Time
LONDON--(BUSINESS WIRE)--Alchemab, a biotech company ... | svhealthin... |
| 04.03.2021 | Pre-clinical data on HOOKIPA’s alternating 2-vector cancer t... | Alternating, intravenous administration of two replicating arenaviral vectors induce tumor-specific ... | globenewsw... |
| 23.02.2021 | CLINIGEN GROUP PLC
Clinigen : Execution of strategy and sim... | 23 February 2021
Execution of strategy and simplification of structure to deliver accelerated mid-t... | marketscre... |
| 23.02.2021 | Clinigen : Execution of strategy and simplification of struc... | 23 February 2021
Execution of strategy and simplification of structure to deliver accelerated mid-t... | marketscre... |
| 23.02.2021 | Clinigen : Half Year Results for the Six Months Ended 31 Dec... | 23 February 2021
Execution of strategy and simplification of structure to deliver accelerated mid-t... | marketscre... |
| 04.11.2019 | Volpi Capital expands team with the appointment of Eszter Sa... | London, 04 November 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private eq... | volpicapit... |
| 05.09.2019 | Volpi Capital completes management buyout of Asolvi | London, 5 September 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private eq... | volpicapit... |
| 20.08.2019 | Volpi Capital makes €20m investment into Mansystems | London, 20 August 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private equi... | volpicapit... |
| 24.06.2019 | CDC Group and London Stock Exchange Group celebrate ‘Compani... | Cairo, Egypt: The second edition of London Stock Exchange Group’s (LSEG) ‘Companies to Inspire Afric... | bii.co.uk/... |
| 05.06.2019 | Volpi Capital expands team with the appointment of Joerg Kla... | London, 05 June 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private equity... | volpicapit... |
| 07.03.2019 | CycloMedia Acquires Floating Point FX to Fuel US and Interna... | Acquisition Strengthens CycloMedia’s US Presence, Enhances Data Analytics Capabilities
Zaltbommel, ... | volpicapit... |
| 06.03.2019 | Volpi Capital expands its investment team with the appointme... | London, 6 March 2019: Volpi Capital (“Volpi”), a specialist European lower mid-market private equity... | volpicapit... |
| 06.09.2017 | Congenica’s Sapientia™ selected for Portugal’s In2Genome gen... | Congenica’s Sapientia™ selected for Portugal’s In2Genome genetic disease diagnosis project
06-09-20... | cambridgen... |
| 05.09.2017 | AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in F... | Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment F... | 3bfuturehe... |
| 30.06.2017 | Marshall Group and Hill agree joint venture to bring hundred... | Marshall Group and Hill agree joint venture to bring hundreds of new homes to Cambridge
30-06-2017
... | cambridgen... |
| 27.06.2017 | Mission Therapeutics appoints Scientific Advisory Board | Mission Therapeutics appoints Scientific Advisory Board
27-06-2017
Mission Therapeutics, a Babraha... | cambridgen... |
| 22.06.2017 | China’s '100K Wellness Pioneer Project' uses UniteGen and Sa... | China’s '100K Wellness Pioneer Project' uses UniteGen and Sapientia™ integrated platform
22-06-2017... | cambridgen... |
| 13.06.2017 | First accommodation milestone complete at University of Camb... | First accommodation milestone complete at University of Cambridge’s new district, Eddington
13-06-2... | cambridgen... |
| 05.06.2017 | F-star expands its relationship with Merck through a new str... | F-star expands its relationship with Merck through a new strategic collaboration
05-06-2017
F-star... | cambridgen... |
| 05.06.2017 | F-star expands its relationship with Merck through a new str... | F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new pa... | cambridgen... |
| 15.03.2017 | Autifony Therapeutics obtains £1.3 million in funding from I... | London, UK - 15th March 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the d... | svhealthin... |
| 27.02.2017 | Congenica raises £8M ($10M) in Series B financing round to d... | Congenica, a leading provider of clinical genome analysis technology, announced today that it has ra... | cambridgen... |
| 27.02.2017 | Congenica raises £8M ($10M) in Series B financing round to d... | Congenica raises £8M ($10M) in Series B financing round to drive international expansion
27-02-2017... | cambridgen... |
| 16.01.2017 | Quercus Realises More Than a 9% Return on the Disposal of It... | MILAN & LONDON & DUBAI, United Arab Emirates–(BUSINESS WIRE)–January 16, 2017–
Quercus Asse... | venturebea... |
| 09.12.2016 | Quercus Announces the €150 Million First Close of its New Re... | LONDON & ROME & LUXEMBOURG–(BUSINESS WIRE)–December 9, 2016–
Quercus Assets Selection, whic... | venturebea... |
| 10.12.2015 | ImmBio initiates first-in-human studies of its novel pneumoc... | ImmBio initiates first-in-human studies of its novel pneumococcal vaccine, PnuBioVax
10-12-2015
Im... | cambridgen... |
| 15.10.2015 | Crescendo Biologics launches new strategy in oncology drug d... | Crescendo Biologics launches new strategy in oncology drug discovery & development
15-10-2015
... | cambridgen... |
| 12.06.2015 | Work begins on cutting-edge zero carbon development at Great... | Work begins on cutting-edge zero carbon development at Great Kneighton
12-06-2015
Leading housebui... | cambridgen... |
| - | Neuromodulation pioneer WISE closes EUR 15M Series C financi... | October 1, 2020
WISE Srl, a medical device company developing next-generation implantable leads for... | htgf.de/en... |
| - | Mission Therapeutics Welcomes Co-founder of Rosetta Capital,... | CAMBRIDGE, England--(BUSINESS WIRE)--Mar 24, 2021--
Mission Therapeutics (“Mission”), a drug discov... | oaoa.com/n... |
| - | AMAL Therapeutics finalises €29 million (CHF 33.2 million) S... | November 12, 2018
AMAL Therapeutics SA (AMAL), a Swiss biotech developing peptide-based therapeut... | htgf.de/en... |
| - | Pharm2Farm: Revolutionary Anti-viral Face Mask Kills 99.9% o... | NOTTINGHAM, England--(BUSINESS WIRE)--Mar 11, 2021--
A new anti-viral mask which kills 99.9% of Cov... | oaoa.com/n... |
| - | Downing FOUR VCT Healthcare Share Class open for tax year-en... | As the tax year draws to a close, the Downing FOUR Venture Capital Trust (VCT) Healthcare Share Clas... | downing.co... |
| - | Amal Therapeutics raises CHF 3 million in a Series A financi... | March 30, 2016
Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financi... | htgf.de/en... |
